Clinical Trials Logo

Renal Failure, Chronic clinical trials

View clinical trials related to Renal Failure, Chronic.

Filter by:

NCT ID: NCT03246984 Not yet recruiting - Clinical trials for Kidney Failure, Chronic

VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ

VALUE
Start date: September 2017
Phase: N/A
Study type: Interventional

This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic AV fistula. Up to 50 patients will be enrolled. All patients will be implanted with the VasQ device, a subcutaneous arteriovenous conduit support for vascular access. The follow up period in this study will be for a duration of 12 months, with follow up visits scheduled at 1, 3, 6, 9, and 12 months.

NCT ID: NCT03093740 Not yet recruiting - Hepatitis C Clinical Trials

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

NCT ID: NCT02332811 Completed - Clinical trials for Renal Failure Chronic

An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients

TOSCANA
Start date: October 2013
Phase: Phase 3
Study type: Interventional

Primary Objective: Evaluate the reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis Secondary Objective: Evaluate the safety on the basis of adverse events, changes in laboratory values and vital signs from baseline (Day 0) to Day 56 (End of treatment/ End of Study)

NCT ID: NCT02259296 Not yet recruiting - Clinical trials for Renal Failure, Chronic

Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure

TACTIC
Start date: January 2015
Phase: N/A
Study type: Interventional

The timing for arteriovenous fistula (AVF) creation and its effect on target organs in patients with chronic renal failure will be investigated by multicenter prospective cohort. Lower estimated glomerular filtration rate (eGFR) patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) and higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) will be proposed to undertake AVF creation. Maturation rate and time of AVF will be followed up in 3 months; primary and secondary patency rate of AVF, AVF construction on cardiac structure, function, encephalopathy, cerebral vascular lesions and cognitive function will be followed up in the next 2 years. This multicenter will provide evidence to develop guideline of timing for AVF creation

NCT ID: NCT01875523 Completed - Clinical trials for End-Stage Renal Disease

PK of Serelaxin in Severe Renal Impairment and ESRD

CRLX030A2102
Start date: August 2013
Phase: Phase 1
Study type: Interventional

The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.

NCT ID: NCT00664066 Terminated - Anemia Clinical Trials

DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)

DELFT
Start date: April 2008
Phase: N/A
Study type: Observational

This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect & describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.

NCT ID: NCT00439023 Completed - Clinical trials for Renal Failure, Chronic

Glucose in Dialysis Water in Non-diabetics

Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purposes are 1. to measure the effect of dialysis with glucose on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations of glucagon, growth hormone, renin, angiotensin II, endothelin and body temperature, and 2. to analysis the relationship between changes in blood pressure on the one hand and changes in vasoactive hormones on the other

NCT ID: NCT00438503 Completed - Clinical trials for Diabetic Nephropathies

Glucose in Dialysis Water in Diabetics With Chronic Renal Failure

Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin II, endothelin and body temperature, and 2. to analyse the relationship between the changes in blood pressure and changes in vasoactive hormones

NCT ID: NCT00438295 Completed - Clinical trials for Renal Failure, Chronic

Temperature Control During Dialysis Treatment

Start date: August 2006
Phase: Phase 4
Study type: Interventional

The purpose is to measure the effect of glucose in the dialysis water on blood pressure, pulse rate, and plasma glucose with and without body temperature control

NCT ID: NCT00337935 Completed - Anemia Clinical Trials

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to show that giving PROCRIT (Epoetin alfa) every 2 weeks to increase the hemoglobin (Hb) level and then to adjust the PROCRIT (Epoetin alfa) dose every 4 weeks (Q4W) to maintain Hb levels, is safe and effective in patients with anemia from Chronic Kidney Disease (CKD), not on dialysis, who reside in long-term care facilities. In this study the frequency of PROCRIT (Epoetin alfa) dosing is under investigation.